Sorted By Test Name - Mayo Medical Laboratories

9829
SMART
89537
MEAD
82890
Company, 1985, pp 56-58 2. Koss LG: Diagnostic Cytology and itâ€s Histopathologic Bases.
Philadelphia, JB Lippincott Company, 1992, pp 300-301
May-Grunwald Giemsa Stain for Hematologic and Nuclear
Elements
Reference Values:
The laboratory will provide a pathology consultation and stained slide.
Mayo Stratification for Myeloma and Risk-Adapted Therapy
Report
Clinical Information: Multiple myeloma is increasingly recognized as a disease characterized by
marked cytogenetic, molecular, and proliferative heterogeneity. This heterogeneity is manifested
clinically by varying degrees of disease aggressiveness. Multiple myeloma patients with more aggressive
disease experience suboptimal responses to some therapeutic approaches; therefore, identifying these
patients is critically important for selecting appropriate treatment options. The Mayo Stratification for
Myeloma and Risk-Adapted Therapy (mSMART) algorithm classifies patients into either standard or
high-risk categories based on the results of 3 assays: the plasma cell labeling index profile (PCLI),
conventional chromosome analysis, and FISH for specific multiple myeloma-associated abnormalities.
High-risk group (25% of patients) are those with any of the following: -PCLI result of > or =3%
-Hypodiploidy (identified by chromosome analysis) -t(4;14), t(14;16) or deletion of 17p (detected by
FISH) Standard-risk group (75% of patients) includes those with: -PCLI 1.5% associated with more aggressive disease
CHROMOSOMES, mSMART EVALUATION
46,XX or 46,XY. No apparent chromosome abnormality.
An interpretative report will be provided.
PLASMA CELL PROLIFRATIVE DISORDER (PCPD)
An interpretative report will be provided.
Clinical References: 1. Dispenzieri A, Rajkumar SV, Gertz MA, et al: Treatment of newly
diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-Adapted Therapy
(mSMART): consensus statement. Mayo Clin Proc 2007 Mar;82(3):323-341 2. Fonseca R, Blood E, Rue
M, et al: Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003 Jun
1;101(11):4569-4575 3. Greipp PR, Witzig TE, Gonchoroff TM, et al: Immunofluorescence labeling
indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc 1987 Nov:62(11):969-977
Meadow Fescue, IgE
Clinical Information: Clinical manifestations of immediate hypersensitivity (allergic) diseases are
caused by the release of proinflammatory mediators (histamine, leukotrienes, and prostaglandins) from
immunoglobulin E (IgE)-sensitized effector cells (mast cells and basophils) when cell-bound IgE
antibodies interact with allergen. In vitro serum testing for IgE antibodies provides an indication of the
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 1165